These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 12623898)
1. Bayer is forced to release documents over withdrawal of cerivastatin. Marwick C BMJ; 2003 Mar; 326(7388):518. PubMed ID: 12623898 [No Abstract] [Full Text] [Related]
2. The withdrawal of Baycol (cerivastatin). Griffin JP Adverse Drug React Toxicol Rev; 2001 Dec; 20(4):177-80. PubMed ID: 11770168 [No Abstract] [Full Text] [Related]
4. Bayer's response to "potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis". Piorkowski JD JAMA; 2004 Dec; 292(21):2655-7; discussion 2658-9. PubMed ID: 15572725 [No Abstract] [Full Text] [Related]
6. Substituting for cerivastatin (Baycol). Med Lett Drugs Ther; 2001 Sep; 43(1113):79-80. PubMed ID: 11581579 [No Abstract] [Full Text] [Related]
7. Baycol withdrawn from market. SoRelle R Circulation; 2001 Aug; 104(8):E9015-6. PubMed ID: 11521677 [No Abstract] [Full Text] [Related]
8. [Withdrawal of cerivastatin revealed a flaw of post-marketing surveillance system in the United States]. Saito M; Hirata-Koizumi M; Miyake S; Hasegawa R Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2005; (123):41-5. PubMed ID: 16541751 [TBL] [Abstract][Full Text] [Related]
9. Cerivastatin withdrawn from market. Thompson CA Am J Health Syst Pharm; 2001 Sep; 58(18):1685. PubMed ID: 11571807 [No Abstract] [Full Text] [Related]
11. Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis. Psaty BM; Furberg CD; Ray WA; Weiss NS JAMA; 2004 Dec; 292(21):2622-31. PubMed ID: 15572720 [TBL] [Abstract][Full Text] [Related]
12. Rhabdomyolysis and cerivastatin: was it a problem of dose? Kalaria D; Wassenaar W CMAJ; 2002 Oct; 167(7):737. PubMed ID: 12389822 [No Abstract] [Full Text] [Related]
13. Bayer to settle lawsuits over Baycol. Health News; 2004 Sep; 10(9):2. PubMed ID: 15597437 [No Abstract] [Full Text] [Related]
14. The cerivastatin withdrawal crisis: a "post-mortem" analysis. Maggini M; Raschetti R; Traversa G; Bianchi C; Caffari B; Da Cas R; Panei P Health Policy; 2004 Aug; 69(2):151-7. PubMed ID: 15212862 [TBL] [Abstract][Full Text] [Related]
15. Rhabdomyolysis associated with cerivastatin plus gemfibrozil combined regimen. Marsà Carretero M; Alos Manrique C; Valles Callol JA Br J Gen Pract; 2002 Mar; 52(476):235-6. PubMed ID: 12030671 [No Abstract] [Full Text] [Related]
16. [Fatal rhabdomyolysis caused by cerivastatin]. Scheen AJ Rev Med Liege; 2001 Aug; 56(8):592-4. PubMed ID: 11584446 [TBL] [Abstract][Full Text] [Related]
17. [Myopathy with rhabdomyolysis as an adverse effect of simultaneous treatment with cerivastatin and gemfibrozil]. Huić M; Anić B; Cikes N; Bosnić D; Sentić M; Markeljević J; Mayer M; Pazanin L Lijec Vjesn; 2002; 124(3-4):73-6. PubMed ID: 18956824 [TBL] [Abstract][Full Text] [Related]
18. [Cerivastatin and acute kidney failure caused by rhabdomyolysis]. Bravo JJ; Novoa D; Romero R; Sánchez-Guisande D Nefrologia; 2001; 21(5):509. PubMed ID: 11795023 [No Abstract] [Full Text] [Related]
19. Cerivastatin and reports of fatal rhabdomyolysis. Staffa JA; Chang J; Green L N Engl J Med; 2002 Feb; 346(7):539-40. PubMed ID: 11844864 [No Abstract] [Full Text] [Related]
20. [Rhabdomyolysis, acute renal failure and use of cerivastatin combined with gemfibrozil. New evidence]. SantaCruz PL; González A; León ME; Fernández MY Nefrologia; 2002; 22(3):301-2. PubMed ID: 12123135 [No Abstract] [Full Text] [Related] [Next] [New Search]